PDS Biotech appoints Lars Boesgaard as chief financial officer

A businessman joins a new employee to the team as its leader. Hiring new employees for the project., teamwork. leader works with the team as a member. increasing efficiency, confidence, communication

PDS Biotechnology Corp., a Princeton-based firm developing a pipeline of targeted cancer immunotherapies and infectious disease vaccines, on Tuesday announced the appointment of Lars Boesgaard as chief financial officer, effective Dec. 4.

Boesgaard succeeds Matthew Hill, who resigned as PDS Biotech’s CFO to pursue other professional endeavors.

“We are delighted to welcome Lars to the PDS Biotech team. He is an experienced CFO with an impressive track record of guiding biotech companies to create strategic growth. I look forward to his insights, as well as his financial expertise and oversight, as we continue to mature our business and advance our lead targeted cancer immunotherapy clinical candidates towards commercialization,” Frank Bedu-Addo, CEO and president of PDS Biotech, said. “Additionally, we would like to thank Matt for his contributions to PDS Biotech’s progress and wish him all the best in his new role.”

Boesgaard has had a career spanning more than 25 years in health care and has deep capital markets and investor relations experience with global clinical and commercial-stage pharmaceutical and biotechnology companies. He has prepared and executed corporate transactions and built financial frameworks for rapidly growing organizations.

Prior to joining PDS Biotech, Boesgaard served as CFO of AM-Pharma B.V. from September 2021 to August. Boesgaard also served as CFO of Columbia Care from August 2018 to August 2021, where he completed key transactions including an initial public offering/reverse merger resulting in a $120 million capital infusion and raising $200 million in public equity and debt offerings.

Boesgaard was also previously the vice president and CFO of Roka Bioscience from November 2015 to July 2018 and held several other senior finance positions with publicly traded companies, including Insulet Corp., Alexion Pharmaceuticals and Novo Nordisk A/S.

“I’m excited to join PDS Biotech as the company advances its robust pipeline of groundbreaking targeted cancer immunotherapies,” Boesgaard said. “I look forward to working with the team to help drive PDS Biotech’s business strategy and financial growth.”